- First-of-its-Kind Research Collaboration for Takeda and
Boston Medical Center with the Aim to Decarbonize the Health Care
Value Chain
- Three-Year Collaboration to Tackle Carbon Emissions from
Regulated Medical Waste, Including Pharmaceutical
Packaging
- Learnings will be Shared to Scale Decarbonization Solutions
Across the Health Care Value Chain
Takeda (TOKYO:4502/NYSE:TAK) and Boston Medical Center
(BMC) today announced a new collaboration focused on identifying
innovative solutions that can reduce hard-to-abate greenhouse gas
(GHG) emissions in the health care sector. The collaboration
between Takeda and BMC aims to reduce the GHG emissions caused by
disposal of regulated medical waste, such as pharmaceutical
packaging and single-use plastics, which are among the most
difficult environmental challenges facing the industry. The effort
will also seek to scale the interventions developed through the
collaboration by sharing best practices to help other organizations
adopt and learn new ways to decarbonize in their operations to
drive wider health care ecosystem impact.
“At BMC, as a national leader in environmental excellence, we
have long recognized that sustainability is health care,” said
Robert Biggio, Senior Vice President and Chief Sustainability &
Real Estate Officer at Boston Medical Center Health System.
“Increasing health risks exacerbated by climate change, such as
extreme heat, pollution, biodiversity loss and other environmental
impacts are a real and direct threat to patient and community
wellbeing. Our collaboration with Takeda aims to drive meaningful
change by tackling environmental challenges that contribute to
health disparities in many communities. This collaboration is a
critical step in driving innovation in the medical supply chain
that can be shared with other health care organizations for a
healthier environment for all communities.”
A key objective of this collaboration is to effectively
identify, pilot and share valuable insights on decarbonization
solutions that other healthcare organizations can adopt as they
also seek to reduce greenhouse gas emissions. This may include
engaging with other industry stakeholders, such as suppliers, waste
vendors, and packaging providers to share and establish new best
practices and practical applications.
As a part of this collaboration, Boston Medical Center will
conduct waste audits across key clinical areas to identify emission
hotspots and pilot new technologies aimed at reducing emissions
from the disposal of regulated medical waste, including
pharmaceutical packaging. BMC, recognized with multiple Practice
Greenhealth Top 25 Environmental Excellence Awards, is the first
hospital in the nation to leverage a rooftop solar array to provide
energy bill credit to eligible patients facing energy insecurity.
The hospital built two rooftop farms supplying fresh produce for
the hospital's food pantry, patient meals and local community
organizations, and opened the first net-zero ready for energy
behavioral health facility—among other leading initiatives. BMC was
also the first nonprofit health care organization in the country to
issue sustainability bonds with a $232 million bond sale for campus
renovations to better support patient care.
“Takeda understands the undeniable connection between human and
planetary health,” said Teresa Bitetti, president of Takeda’s
global oncology business unit. “To help us develop solutions and
tackle some of the most difficult environmental challenges the
health care industry is facing, we need bold collaborations with
organizations like BMC. We are proud to partner with BMC, an
organization that shares our commitment to advancing environmental
sustainability, improving patient health and supporting innovations
across the broader healthcare ecosystem.”
For Takeda, this collaboration supports its ambitious climate
goal to reach net-zero greenhouse gas (GHG) emissions in its
operations by 2035 and across our value chain by 2040. In 2024, the
Science Based Targets initiative (SBTi) validated Takeda’s net zero
GHG emission goals as being consistent with reductions required to
limit the rise in global temperature to 1.5°C above pre-industrial
levels.
About Takeda Takeda is focused on creating better health
for people and a brighter future for the world. We aim to discover
and deliver life-transforming treatments in our core therapeutic
and business areas, including gastrointestinal and inflammation,
rare diseases, plasma-derived therapies, oncology, neuroscience and
vaccines. Together with our partners, we aim to improve the patient
experience and advance a new frontier of treatment options through
our dynamic and diverse pipeline. As a leading values-based,
R&D-driven biopharmaceutical company headquartered in Japan, we
are guided by our commitment to patients, our people and the
planet. We serve patients in approximately 80 countries and regions
driven by our purpose and are grounded in the values that have
defined us for more than two centuries. For more information, visit
www.takeda.com.
About Boston Medical Center Boston Medical Center models
a new kind of excellence in healthcare, where innovative and
equitable care empowers all patients to thrive. We combine
world-class clinicians and cutting-edge treatments with
compassionate, quality care that extends beyond our walls. As an
award-winning health equity leader, our diverse clinicians and
staff interrogate racial disparities in care and partner with our
community to dismantle systemic inequities. And as a national
leader in research and the teaching affiliate for Boston University
Chobanian & Avedisian School of Medicine, we’re driving the
future of care.
Important Notice For the purposes of this notice, “press
release” means this document, any oral presentation, any question
and answer session and any written or oral material discussed or
distributed by Takeda Pharmaceutical Company Limited (“Takeda”)
regarding this release. This press release (including any oral
briefing and any question-and-answer in connection with it) is not
intended to, and does not constitute, represent or form part of any
offer, invitation or solicitation of any offer to purchase,
otherwise acquire, subscribe for, exchange, sell or otherwise
dispose of, any securities or the solicitation of any vote or
approval in any jurisdiction. No shares or other securities are
being offered to the public by means of this press release. No
offering of securities shall be made in the United States except
pursuant to registration under the U.S. Securities Act of 1933, as
amended, or an exemption therefrom. This press release is being
given (together with any further information which may be provided
to the recipient) on the condition that it is for use by the
recipient for information purposes only (and not for the evaluation
of any investment, acquisition, disposal or any other transaction).
Any failure to comply with these restrictions may constitute a
violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns
investments are separate entities. In this press release, “Takeda”
is sometimes used for convenience where references are made to
Takeda and its subsidiaries in general. Likewise, the words “we”,
“us” and “our” are also used to refer to subsidiaries in general or
to those who work for them. These expressions are also used where
no useful purpose is served by identifying the particular company
or companies.
Forward-Looking Statements This press release and any
materials distributed in connection with this press release may
contain forward-looking statements, beliefs or opinions regarding
Takeda’s future business, future position and results of
operations, including estimates, forecasts, targets and plans for
Takeda. Without limitation, forward-looking statements often
include words such as “targets”, “plans”, “believes”, “hopes”,
“continues”, “expects”, “aims”, “intends”, “ensures”, “will”,
“may”, “should”, “would”, “could”, “anticipates”, “estimates”,
“projects” or similar expressions or the negative thereof. These
forward-looking statements are based on assumptions about many
important factors, including the following, which could cause
actual results to differ materially from those expressed or implied
by the forward-looking statements: the economic circumstances
surrounding Takeda’s global business, including general economic
conditions in Japan and the United States; competitive pressures
and developments; changes to applicable laws and regulations,
including global health care reforms; challenges inherent in new
product development, including uncertainty of clinical success and
decisions of regulatory authorities and the timing thereof;
uncertainty of commercial success for new and existing products;
manufacturing difficulties or delays; fluctuations in interest and
currency exchange rates; claims or concerns regarding the safety or
efficacy of marketed products or product candidates; the impact of
health crises, like the novel coronavirus pandemic, on Takeda and
its customers and suppliers, including foreign governments in
countries in which Takeda operates, or on other facets of its
business; the timing and impact of post-merger integration efforts
with acquired companies; the ability to divest assets that are not
core to Takeda’s operations and the timing of any such
divestment(s); and other factors identified in Takeda’s most recent
Annual Report on Form 20-F and Takeda’s other reports filed with
the U.S. Securities and Exchange Commission, available on Takeda’s
website at:
https://www.takeda.com/investors/sec-filings-and-security-reports/
or at www.sec.gov. Takeda does not undertake to update any of the
forward-looking statements contained in this press release or any
other forward-looking statements it may make, except as required by
law or stock exchange rule. Past performance is not an indicator of
future results and the results or statements of Takeda in this
press release may not be indicative of, and are not an estimate,
forecast, guarantee or projection of Takeda’s future results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241024567079/en/
Takeda Media Relations: media_relations@takeda.com
BMC Media Relations: communications@bmc.org
Takeda Pharmaceutical (NYSE:TAK)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Takeda Pharmaceutical (NYSE:TAK)
Historical Stock Chart
Von Nov 2023 bis Nov 2024
